Matthew P Humphries

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7806469/publications.pdf

Version: 2024-02-01

39 papers 4,604 citations

16 h-index 325983 40 g-index

40 all docs

40 docs citations

times ranked

40

8848 citing authors

#	Article	IF	CITATIONS
1	Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer. British Journal of Cancer, 2022, 126, 247-258.	2.9	14
2	Identification of a prognostic signature in colorectal cancer using combinatorial algorithmâ€driven analysis. Journal of Pathology: Clinical Research, 2022, , .	1.3	1
3	Bridging the gap with the UK Genomics Pathology Imaging Collection. Nature Medicine, 2022, 28, 1107-1108.	15.2	7
4	Identifying mismatch repairâ€deficient colon cancer: nearâ€perfect concordance between immunohistochemistry and microsatellite instability testing in a large, populationâ€based series. Histopathology, 2021, 78, 401-413.	1.6	55
5	In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 288-300.	3.2	13
6	QuPath: The global impact of an open source digital pathology system. Computational and Structural Biotechnology Journal, 2021, 19, 852-859.	1.9	49
7	Evolutionary genetic algorithm identifies <i>IL2RB</i> as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer. NAR Genomics and Bioinformatics, 2021, 3, Iqab016.	1.5	10
8	Colonic epithelial cathelicidin (<scp>LL</scp> â€37) expression intensity is associated with progression of colorectal cancer and presence of <scp>CD8</scp> ⁺ T cell infiltrate. Journal of Pathology: Clinical Research, 2021, 7, 495-506.	1.3	8
9	The clinical and molecular significance associated with STING signaling in breast cancer. Npj Breast Cancer, 2021, 7, 81.	2.3	21
10	A Means of Assessing Deep Learning-Based Detection of ICOS Protein Expression in Colon Cancer. Cancers, 2021, 13, 3825.	1.7	17
11	The Potential of Digital Image Analysis to Determine Tumor Cell Content in Biobanked Formalin-Fixed, Paraffin-Embedded Tissue Samples. Biopreservation and Biobanking, 2021, 19, 324-331.	0.5	5
12	Orthogonal <i>MET</i> analysis in a populationâ€representative stage IIâ€"III colon cancer cohort: prognostic and potential therapeutic implications. Molecular Oncology, 2021, 15, 3317-3328.	2.1	3
13	HistoClean: Open-source software for histological image pre-processing and augmentation to improve development of robust convolutional neural networks. Computational and Structural Biotechnology Journal, 2021, 19, 4840-4853.	1.9	5
14	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. Cancer Discovery, 2021, 11, 1212-1227.	7.7	139
15	PD-L1 Multiplex and Quantitative Image Analysis for Molecular Diagnostics. Cancers, 2021, 13, 29.	1.7	11
16	Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. British Journal of Cancer, 2020, 123, 1280-1288.	2.9	45
17	A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment. Molecular Oncology, 2020, 14, 2384-2402.	2.1	71
18	Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization. Cancers, 2020, 12, 1114.	1.7	34

#	Article	IF	CITATIONS
19	The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation. BMC Cancer, 2020, 20, 500.	1.1	20
20	Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer. Journal of Oncology, 2020, 2020, 1-10.	0.6	7
21	Comparison of different antiâ€Ki67 antibody clones and hotâ€spot sizes for assessing proliferative index and grading in pancreatic neuroendocrine tumours using manual and image analysis. Histopathology, 2020, 77, 646-658.	1.6	16
22	FGFR1 Expression and Role in Migration in Low and High Grade Pediatric Gliomas. Frontiers in Oncology, $2019,9,103.$	1.3	12
23	Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities. Journal of Thoracic Oncology, 2019, 14, 45-53.	0.5	42
24	Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. Journal of Oncology, 2018, 2018, 1-14.	0.6	44
25	Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer. Journal of Pathology: Clinical Research, 2018, 4, 241-249.	1.3	12
26	Characterising the adipose-inflammatory microenvironment in male breast cancer. Endocrine-Related Cancer, 2018, 25, 773-781.	1.6	6
27	Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. Scientific Reports, 2017, 7, 45293.	1.6	50
28	Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. Journal of Cellular Physiology, 2017, 232, 2246-2252.	2.0	9
29	A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer. Clinical Cancer Research, 2017, 23, 2575-2583.	3.2	16
30	Oestrogen receptor \hat{I}^2 (ER \hat{I}^2) regulates osteogenic differentiation of human dental pulp cells. Journal of Steroid Biochemistry and Molecular Biology, 2017, 174, 296-302.	1.2	12
31	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. Scientific Reports, 2017, 7, 8078.	1.6	14
32	HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. Scientific Reports, 2016, 6, 35121.	1.6	6
33	Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer <i>in vitro</i> . Oncotarget, 2016, 7, 32129-32143.	0.8	19
34	Obesity and male breast cancer: provocative parallels?. BMC Medicine, 2015, 13, 134.	2.3	26
35	The zebrafish reference genome sequence and its relationship to the human genome. Nature, 2013, 496, 498-503.	13.7	3,708
36	Novel Inhibitors of NRH:Quinone Oxidoreductase 2 (NQO2): Crystal Structures, Biochemical Activity, and Intracellular Effects of Imidazoacridin-6-ones. Journal of Medicinal Chemistry, 2011, 54, 6597-6611.	2.9	14

#	Article	IF	CITATIONS
37	Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2. Bioorganic and Medicinal Chemistry, 2010, 18, 696-706.	1.4	21
38	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2832-2836.	1.0	18
39	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7331-7336.	1.0	9